Elicera Therapeutics AB (publ) (STO:ELIC)
Sweden
· Delayed Price · Currency is SEK 5.74
-0.76 (-11.69%)
Mar 9, 2026, 5:29 PM CET
Elicera Therapeutics AB Revenue
In the year 2025, Elicera Therapeutics AB had annual revenue of 10.86M SEK with 52.28% growth. Elicera Therapeutics AB had revenue of 30.00K in the quarter ending December 31, 2025, a decrease of -98.96%.
Revenue
10.86M
Revenue Growth
+52.28%
P/S Ratio
29.06
Revenue / Employee
5.43M
Employees
2
Market Cap
315.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.86M | 3.73M | 52.28% |
| Dec 31, 2024 | 7.13M | -4.10M | -36.52% |
| Dec 31, 2023 | 11.23M | 9.95M | 777.23% |
| Dec 31, 2022 | 1.28M | 1.28M | 217,987.39% |
| Dec 31, 2021 | 587.00 | - | - |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bio-Works Technologies AB | 63.11M |
| Lipum AB | 1.93M |
| Mendus AB | -1.44M |
| Corline Biomedical AB | 8.59M |
| Oncopeptides AB | 71.12M |
| Intervacc AB | 20.09M |
| Xintela AB | 2.28M |
| Sprint Bioscience AB | 167.17M |